新股消息 | 万怡医学递表港交所 致力打造医师学术发展平台

Core Viewpoint - Shanghai Wanyi Medical Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Everbright Securities International as its sole sponsor [1]. Company Overview - Wanyi Medical is a leading AI-driven solution provider in China, focused on empowering physician talent development. It ranks first in the comprehensive AI solution market for medical academia, education, and research in China, according to Frost & Sullivan [4]. - The company has developed an ecosystem connecting physicians and various healthcare participants to accelerate the dissemination of medical knowledge, enhance physician education, and promote the application of research outcomes [4]. - Wanyi Medical offers two main AI-driven revenue-generating solutions: (i) a full-process solution for medical academic activities delivered through the MedEvent platform, and (ii) digital solutions for medical learning and education featuring interactive learning kits tailored to physicians' specialties, interests, and development goals [4]. - The company has launched MedEvidence, a suite of intelligent tools including an AI evidence-based assistant to support end-to-end physician-led research processes, enhancing product functionality and physician engagement [4]. Financial Information - For the fiscal years ending September 30, 2023, 2024, and 2025, the company reported revenues of approximately RMB 239 million, RMB 271 million, and RMB 191 million, respectively [5]. - The annual profits for the same periods were approximately RMB 29.87 million, RMB 29.72 million, and RMB 36.88 million [6]. - The gross profit margins for the fiscal years were recorded at 37.9%, 35.7%, and 42.3% [8]. Market Insights - The market for medical academic, education, and research solutions in China is projected to grow from RMB 66.8 billion in 2019 to RMB 97.6 billion in 2024, with a compound annual growth rate (CAGR) of 7.9%. By 2030, the market size is expected to reach RMB 179.5 billion, with a CAGR of 10.7% from 2024 to 2030 [10]. - The market for comprehensive AI solutions in medical academia, education, and research is expected to grow from RMB 0.9 billion in 2019 to RMB 5.7 billion in 2024, with a CAGR of 45.2%. By 2030, the market is projected to reach RMB 33.9 billion, with a CAGR of 34.8% from 2024 to 2030 [13].